Novo-Nordisk stock heads into the open after a 0.1 percent gain
Published on 09/21/2026 at 07:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo-Nordisk stock closed at USD 43.23 on the NYSE ADR on September 18, 2026, up 0.10 percent from the prior session. The shares moved within an intraday range between USD 42.78 and USD 43.54, with reported volume of about 10,360,000 shares for the day.
September 18, 2026 in numbers
Novo-Nordisk A/S (ISIN DK0062498333, NYSE: NVO) saw its NYSE ADR finish the last completed United States session at USD 43.23 on September 18, 2026, according to price data cited by MarketBeat and related coverage. The same data set for that session shows an intraday low near USD 42.78 and an intraday high around USD 43.54, placing the closing price toward the upper half of the daily range and within the documented 52-week span from roughly USD 35.12 to USD 64.16. Session volume around 10,360,000 ADRs indicated active trading through the United States close.
As Ad-hoc-news summarized, Novo-Nordisk stock ended September 18, 2026 at USD 43.23 with that intraday range and a market capitalization around USD 193.04 billion, referencing MarketBeat data for the ADR. In the same wrap, the 52-week interval of approximately USD 35.12 to USD 64.16 underscored how far the shares currently trade below their recent high. Compared with that upper bound, the September 18, 2026 close stood more than USD 20 below the 52-week peak, illustrating a substantial retreat from earlier levels even though the latest session itself showed only a modest percentage gain.
Capital markets day and R&D news today
Company-specific developments frame the outlook today. As Flcube reported, Novo-Nordisk announced on September 18, 2026 that it is acquiring three new obesity research and development programs from biotechnology company Kallyope, broadening its cardiometabolic pipeline beyond existing GLP-1 therapies. In addition, a London market note highlighted that Novo-Nordisk is holding a capital markets day today, September 21, 2026, starting at 09:00 BST, with the event expected to focus on semaglutide strategy and long-term growth assumptions; this schedule and the recent comment that semaglutide might contribute about 75 percent of 2026 sales were cited by Ground News. Together, the fresh R&D acquisitions and today’s capital markets day presentations give investors a detailed look at how Novo-Nordisk plans to sustain obesity and cardiometabolic growth beyond its current GLP-1 franchise as trading in the United States session gets underway.
